Trace gluten contamination may play a role in mucosal and clinical recovery in a subgroup of diet-adherent non-responsive celiac disease patients

BMC Gastroenterology

Alessio Fasano²  Elaine L Leonard Puppa¹  Margaret L Martin¹  Pamela A Cureton²  Justin R Hollon³ 

[1] University of Maryland School of Medicine, Baltimore, MD, USA;Center for Celiac Research, Massachusetts General Hospital and Division of Pediatric Gastroenterology and Nutrition, Massachusetts General Hospital for Children, Boston, MA, USA;Division of Pediatric Gastroenterology and Nutrition, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Brady 320, Baltimore, MD, USA

关键词: Gluten-free diet;    Non-responsive celiac disease;    Refractory sprue;    Refractory celiac disease;    Celiac disease;   

Others  :  858150
DOI  :  10.1186/1471-230X-13-40

 received in 2012-10-26, accepted in 2013-02-25,  发布年份 2013

【 摘 要 】

Background

Patients with persistent symptoms and/or villous atrophy despite strict adherence to a gluten-free diet (GFD) have non-responsive celiac disease (NRCD). A subset of these patients has refractory celiac disease (RCD), yet some NRCD patients may simply be reacting to gluten cross-contamination. Here we describe the effects of a 3-6 month diet of whole, unprocessed foods, termed the Gluten Contamination Elimination Diet (GCED), on NRCD. We aim to demonstrate that this diet reclassifies the majority of patients thought to have RCD type 1 (RCD1).

Methods

We reviewed the records of all GFD-adherent NRCD patients cared for in our celiac center from 2005-2011 who were documented to have started the GCED. Response to the GCED was defined as being asymptomatic after the diet, with normal villous architecture on repeat biopsy, if performed.

Results

Prior to the GCED, all patients were interviewed by an experienced dietitian and no sources of hidden gluten ingestion were identified. 17 patients completed the GCED; 15 were female (88%). Median age at start of the GCED was 42 years (range 6-73). Fourteen patients (82%) responded to the GCED. Six patients met criteria for RCD prior to the GCED; 5 (83%) were asymptomatic after the GCED and no longer meet RCD criteria. Of the 14 patients who responded to the GCED, 11 (79%) successfully returned to a traditional GFD without resurgence of symptoms.

Conclusions

The GCED may be an effective therapeutic option for GFD-adherent NRCD patients. Response to this diet identifies a subgroup of patients, previously classified as RCD1, that is not truly refractory to dietary treatment. Preventing an inaccurate diagnosis of RCD1 avoids immunotherapy. Most patients are able to return to a traditional GFD without return of symptoms.

【 授权许可】

   
2013 Hollon et al; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Fasano A, Berti I, Gerarduzzi T, Not T, Colletti RB, Drago S, Elitsur Y, Green PH, Guandalini S, Hill ID, et al.: Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Intern Med 2003, 163(3):286-292.
• [2]Fasano A, Catassi C: Current approaches to diagnosis and treatment of celiac disease: an evolving spectrum. Gastroenterology 2001, 120(3):636-651.
• [3]Green PH: Where are all those patients with Celiac disease? Am J Gastroenterol 2007, 102(7):1461-1463.
• [4]Nachman F, Maurino E, Vazquez H, Sfoggia C, Gonzalez A, Gonzalez V, Plancer del Campo M, Smecuol E, Niveloni S, Sugai E, et al.: Quality of life in celiac disease patients: prospective analysis on the importance of clinical severity at diagnosis and the impact of treatment. Dig Liver Dis 2009, 41(1):15-25.
• [5]Murray JA, Watson T, Clearman B, Mitros F: Effect of a gluten-free diet on gastrointestinal symptoms in celiac disease. Am J Clin Nutr 2004, 79(4):669-673.
• [6]Abdulkarim AS, Burgart LJ, See J, Murray JA: Etiology of nonresponsive celiac disease: results of a systematic approach. Am J Gastroenterol 2002, 97(8):2016-2021.
• [7]Hall NJ, Rubin G, Charnock A: Systematic review: adherence to a gluten-free diet in adult patients with coeliac disease. Aliment Pharmacol Ther 2009, 30(4):315-330.
• [8]Fine KD, Meyer RL, Lee EL: The prevalence and causes of chronic diarrhea in patients with celiac sprue treated with a gluten-free diet. Gastroenterology 1997, 112(6):1830-1838.
• [9]Freeman HJ, Chopra A, Clandinin MT, Thomson AB: Recent advances in celiac disease. World J Gastroenterol 2011, 17(18):2259-2272.
• [10]Roshan B, Leffler DA, Jamma S, Dennis M, Sheth S, Falchuk K, Najarian R, Goldsmith J, Tariq S, Schuppan D, et al.: The incidence and clinical spectrum of refractory celiac disease in a north american referral center. Am J Gastroenterol 2011, 106(5):923-928.
• [11]Ludvigsson JF, Leffler DA, Bai JC, Biagi F, Fasano A, Green PH, Hadjivassiliou M, Kaukinen K, Kelly CP, Leonard JN, et al.: The Oslo definitions for coeliac disease and related terms. Gut 2013, 62(1):43-52.
• [12]Ho-Yen C, Chang F, van der Walt J, Mitchell T, Ciclitira P: Recent advances in refractory coeliac disease: a review. Histopathology 2009, 54(7):783-795.
• [13]Tau C, Mautalen C, De Rosa S, Roca A, Valenzuela X: Bone mineral density in children with celiac disease. Effect of a Gluten-free diet. Eur J Clin Nutr 2006, 60(3):358-363.
• [14]Rubio-Tapia A, Kelly DG, Lahr BD, Dogan A, Wu TT, Murray JA: Clinical staging and survival in refractory celiac disease: a single center experience. Gastroenterology 2009, 136(1):99-107. quiz 352-103
• [15]Rubio-Tapia A, Murray JA: Classification and management of refractory coeliac disease. Gut 2010, 59(4):547-557.
• [16]Malamut G, Afchain P, Verkarre V, Lecomte T, Amiot A, Damotte D, Bouhnik Y, Colombel JF, Delchier JC, Allez M, et al.: Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II. Gastroenterology 2009, 136(1):81-90.
• [17]Daum S, Ipczynski R, Schumann M, Wahnschaffe U, Zeitz M, Ullrich R: High rates of complications and substantial mortality in both types of refractory sprue. Eur J Gastroenterol Hepatol 2009, 21(1):66-70.
• [18]Rostom A, Murray JA, Kagnoff MF: American Gastroenterological Association (AGA) Institute technical review on the diagnosis and management of celiac disease. Gastroenterology 2006, 131(6):1981-2002.
• [19]Price H, Zownir J, Prokipchuk E: Letter: Coeliac disease. Lancet 1975, 2(7941):920-921.
• [20]Oberhuber G, Granditsch G, Vogelsang H: The histopathology of coeliac disease: time for a standardized report scheme for pathologists. Eur J Gastroenterol Hepatol 1999, 11(10):1185-1194.
• [21]Hill ID, Dirks MH, Liptak GS, Colletti RB, Fasano A, Guandalini S, Hoffenberg EJ, Horvath K, Murray JA, Pivor M, et al.: Guideline for the diagnosis and treatment of celiac disease in children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2005, 40(1):1-19.
• [22]Akobeng AK, Thomas AG: Systematic review: tolerable amount of gluten for people with coeliac disease. Aliment Pharmacol Ther 2008, 27(11):1044-1052.
• [23]Catassi C, Fabiani E, Iacono G, D'Agate C, Francavilla R, Biagi F, Volta U, Accomando S, Picarelli A, De Vitis I, et al.: A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease. Am J Clin Nutr 2007, 85(1):160-166.
• [24]Biagi F, Campanella J, Martucci S, Pezzimenti D, Ciclitira PJ, Ellis HJ, Corazza GR: A milligram of gluten a day keeps the mucosal recovery away: a case report. Nutr Rev 2004, 62(9):360-363.
• [25]Thompson T, Lee AR, Grace T: Gluten contamination of grains, seeds, and flours in the United States: a pilot study. J Am Diet Assoc 2010, 110(6):937-940.
• [26]Dewar DH, Donnelly SC, McLaughlin SD, Johnson MW, Ellis HJ, Ciclitira PJ: Celiac disease: management of persistent symptoms in patients on a gluten-free diet. World J Gastroenterol 2012, 18(12):1348-1356.
• [27]Leffler DA, Dennis M, Hyett B, Kelly E, Schuppan D, Kelly CP: Etiologies and predictors of diagnosis in nonresponsive celiac disease. Clin Gastroenterol Hepatol 2007, 5(4):445-450.
• [28]Goerres MS, Meijer JW, Wahab PJ, Kerckhaert JA, Groenen PJ, Van Krieken JH, Mulder CJ: Azathioprine and prednisone combination therapy in refractory coeliac disease. Aliment Pharmacol Ther 2003, 18(5):487-494.
• [29]Lanzini A, Lanzarotto F, Villanacci V, Mora A, Bertolazzi S, Turini D, Carella G, Malagoli A, Ferrante G, Cesana BM, et al.: Complete recovery of intestinal mucosa occurs very rarely in adult coeliac patients despite adherence to gluten-free diet. Aliment Pharmacol Ther 2009, 29(12):1299-1308.
• [30]Tursi A, Brandimarte G, Giorgetti GM: Lack of usefulness of anti-transglutaminase antibodies in assessing histologic recovery after gluten-free diet in celiac disease. J Clin Gastroenterol 2003, 37(5):387-391.
• [31]Sugai E, Nachman F, Vaquez H, Gonzalez A, Andrenacci P, Czech A, Niveloni S, Mazure R, Smecuol E, Cabanne A, et al.: Dynamics of celiac disease-specific serology after initiation of a gluten-free diet and use in the assessment of compliance with treatment. Dig Liver Dis 2010, 42(5):352-358.
• [32]Nachman F, Sugai E, Vazquez H, Gonzalez A, Andrenacci P, Niveloni S, Mazure R, Smecuol E, Moreno ML, Hwang HJ, et al.: Serological tests for celiac disease as indicators of long-term compliance with the gluten-free diet. Eur J Gastroenterol Hepatol 2011, 23(6):473-480.
• [33]Midhagen G, Aberg AK, Olcen P, Jarnerot G, Valdimarsson T, Dahlbom I, Hansson T, Strom M: Antibody levels in adult patients with coeliac disease during gluten-free diet: a rapid initial decrease of clinical importance. J Intern Med 2004, 256(6):519-524.
• [34]Ravelli A, Villanacci V, Monfredini C, Martinazzi S, Grassi V, Manenti S: How patchy is patchy villous atrophy?: distribution pattern of histological lesions in the duodenum of children with celiac disease. Am J Gastroenterol 2010, 105(9):2103-2110.
• [35]Meijer JW, Wahab PJ, Mulder CJ: Small intestinal biopsies in celiac disease: duodenal or jejunal? Virchows Arch 2003, 442(2):124-128.